1. Home
  2. CELU vs RFL Comparison

CELU vs RFL Comparison

Compare CELU & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELU
  • RFL
  • Stock Information
  • Founded
  • CELU 2016
  • RFL 2017
  • Country
  • CELU United States
  • RFL United States
  • Employees
  • CELU N/A
  • RFL N/A
  • Industry
  • CELU Biotechnology: Pharmaceutical Preparations
  • RFL Real Estate
  • Sector
  • CELU Health Care
  • RFL Finance
  • Exchange
  • CELU Nasdaq
  • RFL Nasdaq
  • Market Cap
  • CELU 42.2M
  • RFL 48.4M
  • IPO Year
  • CELU N/A
  • RFL N/A
  • Fundamental
  • Price
  • CELU $1.98
  • RFL $1.84
  • Analyst Decision
  • CELU
  • RFL
  • Analyst Count
  • CELU 0
  • RFL 0
  • Target Price
  • CELU N/A
  • RFL N/A
  • AVG Volume (30 Days)
  • CELU 75.0K
  • RFL 465.0K
  • Earning Date
  • CELU 05-08-2025
  • RFL 06-11-2025
  • Dividend Yield
  • CELU N/A
  • RFL N/A
  • EPS Growth
  • CELU N/A
  • RFL N/A
  • EPS
  • CELU N/A
  • RFL N/A
  • Revenue
  • CELU $54,220,000.00
  • RFL $732,000.00
  • Revenue This Year
  • CELU $23.29
  • RFL N/A
  • Revenue Next Year
  • CELU N/A
  • RFL N/A
  • P/E Ratio
  • CELU N/A
  • RFL N/A
  • Revenue Growth
  • CELU 138.11
  • RFL 35.56
  • 52 Week Low
  • CELU $1.00
  • RFL $1.27
  • 52 Week High
  • CELU $5.22
  • RFL $3.19
  • Technical
  • Relative Strength Index (RSI)
  • CELU 51.94
  • RFL 52.36
  • Support Level
  • CELU $1.80
  • RFL $1.56
  • Resistance Level
  • CELU $2.26
  • RFL $2.04
  • Average True Range (ATR)
  • CELU 0.18
  • RFL 0.15
  • MACD
  • CELU 0.02
  • RFL -0.01
  • Stochastic Oscillator
  • CELU 48.25
  • RFL 52.56

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: